Back

Assessing the achievability of optimal therapy in patients with heart failure with reduced ejection fraction; a difficult task?

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pharmacotherapy 1 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Miss Florence Bernier

Quebec Heart and Lung Institute, Quebec (Canada)

6 More presentations in this session

Presentation thumbnail
Pharmacologic transition in the care of patients with heart failure with reduced ejection fraction - a real life analysis
Doctor I. Cruz (Penafiel, PT)
Abstract Slides
Presentation thumbnail
Risk of safety events considered potential barriers to utilization of guideline-directed medical therapy among patients with worsening heart failure and ejection fraction 30% or lower
Doctor S. Greene (Durham, US)
Abstract Slides
Presentation thumbnail
Clinical outcomes in patients with ischemic versus non-ischemic cardiomyopathy after angiotensin-neprilysin inhibition therapy
Doctor C. Sabanoglu (Ankara, TR)
Abstract Slides
Presentation thumbnail
Five-year retrospective analysis of treatment efficacy effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction with end-stage renal disease
Doctor B. Hsiao (Taipei, TW)
Abstract Slides
Presentation thumbnail
Is downtitration of diuretic therapy safe in patients with heart failure?
Mr C. Geraeds (Maastricht, NL)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - pharmacotherapy 1

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources